Medinice's EGM on October 25, 2024, will vote on issuing up to 1.2 million shares to fund project commercialization
September 27, 2024
Medinice has announced the convening of an Extraordinary General Meeting of Shareholders on October 25, 2025, regarding a potential private issuance of up to 1.2 million Series M shares. The aim of the issuance is to raise capital to complete the certification and support the sale of leading projects currently in the advanced stages of clinical trials, the company stated.
Due to improving market sentiment, growing interest from professional investors, and the upcoming sale of key projects, the company has decided to potentially carry out a private offering of up to 1,200,000 shares. The funds raised through this offering are intended to fully cover the costs of completing clinical trials, obtaining the necessary certifications, and continuing work related to the commercialization of the company’s leading projects, the company also announced.
We Care About Your Privacy
Medinice S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience.
Privacy Policy